Next Treatments
Back to Eczema

AMTX-100 CF

TypeTopical StagePhase 2 Latest updateMay 2, 2025Phase 1/2 results posted

Results

Trial: NCT04313400
Clear or almost clear skinDay 28
Placebo31 people
10 in 100
1.1%26 people
4 in 100
01020
NCT04313400 · Ages 18+ · Results posted May 2025 · This is a summary of trial data for informational purposes only. It is not medical advice.
What is IGA?
  • IGA stands for Investigator Global Assessment.
  • Proportion of responder subjects at Day 28, defined as subjects with both Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™) score of 0 (clear) or 1 (almost clear) (on a 5-point scale) and a reduction of ≥ 2 points from baselineAs this trial registered it · NCT04313400 (the full definition is there)
Why this trial?

AMTX-100 CF has one trial with posted results, and NCT04313400 compared the drug with placebo on a result this page charts.

History

Earliest recorded event: Mar 10, 2020. This timeline shows events collected by Eczema Radar and may not include the treatment’s full history. Study details reflect the latest registry record available here.

  • May 2, 2025Phase 1/2 results postedTopically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis ClinicalTrials.gov NCT04313400
  • Jan 2, 2024Phase 1/2 trial completedTopically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis ClinicalTrials.gov NCT04313400
  • Dec 19, 2023Phase 1/2 main data collectedTopically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis ClinicalTrials.gov NCT04313400
  • Mar 10, 2020Phase 1/2 trial startedTopically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis ClinicalTrials.gov NCT04313400

Sources

Trials